Evidence map›Paper›PMID 31908062›Full record

ArticleSeminars in dialysis2020

Four years into MACRA: What has changed?

Jonathan Cheng, Jackson Kim, Scott D Bieber, Eugene Lin

Abstract read
In one paragraph

Article in Seminars in dialysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. A Roadmap to Excellence: Insights From Quality Structures of Top-Performing Healthcare Organizations.American journal of medical quality : the official journal of the American College of Medical Quality
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jonathan ChengDepartment of Medicine, Division of Nephrology, University of Southern California, Los Angeles, CA, USA.
Jackson KimDepartment of Medicine, Division of Nephrology, University of Southern California, Los Angeles, CA, USA.
Scott D BieberDepartment of Medicine, Division of Nephrology, University of Washington, Seattle, WA, USA.
Eugene LinDepartment of Medicine, Division of Nephrology, University of Southern California, Los Angeles, CA, USA.ORCID 0000-0002-3559-5134

Funding

Investigating the Economic and SocialDeterminants of Home Dialysis Drop-OutK08DK118213 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIN, EUGENE · 2018 to 2022
$854k
NIDDK NIH HHS K08 DK118213
6 · The paper itself

Abstract

In 2015, Congress passed the Medicare Access and CHIP Reauthorization Act (MACRA), a policy intended to transition Medicare away from pure fee-for-service care to value-based care. MACRA does this by evaluating the cost and quality of providers, resulting in financial bonuses and penalties in Medicare reimbursement. MACRA offers two tracks for participation, the Merit-based Incentive Payment System and the Advanced Alternative Payment Models. Although the payment rules are different for each of the tracks, common to both is an emphasis on holding providers accountable for high-quality, cost-efficient care. Early data suggest that the End-stage renal disease Seamless Care Organizations, an Advanced Alternative Payment Model, resulted in cost-savings concurrent with improved care quality. Additionally, on July 10th 2019, the President signed an executive order that further attempts to improve kidney disease care by shifting its focus away from in-center hemodialysis toward chronic kidney disease care, home-based dialysis, kidney transplantation, and innovating new therapies for kidney disease. These changes to nephrology reimbursement present a unique opportunity to improve patient outcomes in a cost-effective way. A multidisciplinary effort among policy makers, nephrology providers, and patient advocacy groups is critical to ensure these changes in care delivery safeguard and improve patient health.

Indexed as

Health PolicyMedicare Access and CHIP Reauthorization Act of 2015Reimbursement MechanismsValue-Based Health InsuranceHumansKidney DiseasesUnited States

Identifiers

PMID31908062
PMCPMC6980361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.